Background and Purpose
Airway hyperresponsiveness (AHR) is a central abnormality in asthma.
Interleukin-5 (IL-5) may modulate AHR in animal models of asthma, but
inconsistent data are available on the impact of targeting IL-5 pathway
against AHR. The difference between targeting IL-5 or IL-5Rα in
modulating AHR remains to be understood in human airways. The aim of
this study was to compare the role of the anti-IL-5Rα benralizumab and
the anti-IL-5 mepolizumab against AHR, and to assess whether these
agents influence the levels of cyclic adenosine monophosphate (cAMP).